

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Ticagrelor

INITIATION

Prerequisites (tick box where appropriate)

- Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned

INITIATION – thrombosis prevention neurological stenting

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient has had a neurological stenting procedure* in the last 60 days
- or
- Patient is about to have a neurological stenting procedure performed*

and

- Patient has demonstrated clopidogrel resistance using the P2Y12 (VerifyNow) assay or another appropriate platelet function assay and requires antiplatelet treatment with ticagrelor
- or

- Clopidogrel resistance has been demonstrated by the occurrence of a new cerebral ischemic event
- or
- Clopidogrel resistance has been demonstrated by the occurrence of transient ischemic attack symptoms referable to the stent.

CONTINUATION – thrombosis prevention neurological stenting

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient is continuing to benefit from treatment
- and
- Treatment continues to be clinically appropriate

INITIATION – Percutaneous coronary intervention with stent deployment

Re-assessment required after 12 months

Prerequisites (tick boxes where appropriate)

- Patient has undergone percutaneous coronary intervention
- and
- Patient has had a stent deployed in the previous 4 weeks
- and
- Patient is clopidogrel-allergic**

INITIATION – Stent thrombosis

Prerequisites (tick box where appropriate)

- Patient has experienced cardiac stent thrombosis whilst on clopidogrel

INITIATION – Myocardial infarction

Re-assessment required after 1 week

Prerequisites (tick box where appropriate)

- For short term use while in hospital following ST-elevated myocardial infarction

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Ward: NHI:

Ticagrelor - continued

INITIATION – acute minor stroke or high-risk transient ischemic attack (TIA)*

Prerequisites (tick boxes where appropriate)

- Patient has been diagnosed with a minor stroke (NIHSS† score 3 or less), high-risk TIA (ABCD2 score 4 or more) or Crescendo TIA
- and
- Patient is expected to be a poor metaboliser of clopidogrel, with documented clinical rationale
- or
- Patient is allergic to clopidogrel**
- and
- Ticagrelor to be prescribed for a maximum of 21 days following minor stroke or TIA

CONTINUATION – subsequent minor stroke or high-risk transient ischemic attack

Re-assessment required after 1 month

Prerequisites (tick box where appropriate)

- Patient has been diagnosed with a minor stroke (NIHSS score 3 or less), high-risk transient ischemic attack (ABCD2 score 4 or more) or Crescendo TIA

Note: Indications marked with * are unapproved indications.

Note: Note:** Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment

Note: Note:NIHSS† National Institutes of Health Stroke Scale.

I confirm that the above details are correct:

Signed: Date: